These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25176981)

  • 21. Blaming the Right Fluorescent in Situ Hybridization.
    Warsame R; Dispenzieri A
    J Clin Oncol; 2015 Nov; 33(33):3976. PubMed ID: 26324369
    [No Abstract]   [Full Text] [Related]  

  • 22. Reply to R. Warsame et al.
    Bochtler T; Hegenbart U; Kunz C; Benner A; Schönland SO
    J Clin Oncol; 2015 Nov; 33(33):3976-7. PubMed ID: 26324370
    [No Abstract]   [Full Text] [Related]  

  • 23. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.
    Palladini G; Russo P; Foli A; Milani P; Lavatelli F; Obici L; Nuvolone M; Brugnatelli S; Invernizzi R; Merlini G
    Ann Hematol; 2012 Jan; 91(1):89-92. PubMed ID: 21533608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
    Charliński G; Wiater E; Jedrzejczak WW
    Pol Merkur Lekarski; 2012 Apr; 32(190):217-20. PubMed ID: 22708276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.
    Reece DE; Hegenbart U; Sanchorawala V; Merlini G; Palladini G; Bladé J; Fermand JP; Hassoun H; Heffner L; Kukreti V; Vescio RA; Pei L; Enny C; Esseltine DL; van de Velde H; Cakana A; Comenzo RL
    Blood; 2014 Oct; 124(16):2498-506. PubMed ID: 25202139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant.
    Brunvand MW; Bitter M
    Haematologica; 2010 Mar; 95(3):519-21. PubMed ID: 19903681
    [No Abstract]   [Full Text] [Related]  

  • 28. Bortezomib in the treatment of AL amyloidosis: targeted therapy?
    Sitia R; Palladini G; Merlini G
    Haematologica; 2007 Oct; 92(10):1302-7. PubMed ID: 18024367
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of light chain deposition disease with bortezomib and dexamethasone.
    Kastritis E; Migkou M; Gavriatopoulou M; Zirogiannis P; Hadjikonstantinou V; Dimopoulos MA
    Haematologica; 2009 Feb; 94(2):300-2. PubMed ID: 19066331
    [No Abstract]   [Full Text] [Related]  

  • 30. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.
    Palladini G; Sachchithanantham S; Milani P; Gillmore J; Foli A; Lachmann H; Basset M; Hawkins P; Merlini G; Wechalekar AD
    Blood; 2015 Jul; 126(5):612-5. PubMed ID: 25987656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis.
    Landau H; Hassoun H; Bello C; Hoover E; Riedel ER; Nimer SD; Comenzo RL
    Amyloid; 2011 Jun; 18 Suppl 1():135-6. PubMed ID: 21838462
    [No Abstract]   [Full Text] [Related]  

  • 32. Sustained improvement in cardiac function with persistent amyloid deposition in a patient with multiple myeloma-associated cardiac amyloidosis treated with bortezomib.
    Tamaki H; Naito Y; Lee-Kawabata M; Taniguchi Y; Hao H; Hirota S; Hasegawa S; Masuyama T; Ogawa H
    Int J Hematol; 2010 Nov; 92(4):655-8. PubMed ID: 20976630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.
    Venner CP; Lane T; Foard D; Rannigan L; Gibbs SD; Pinney JH; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
    Blood; 2012 May; 119(19):4387-90. PubMed ID: 22331187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Current treatment of AL amyloidosis].
    Desport E; Moumas E; Abraham J; Delbès S; Lacotte-Thierry L; Touchard G; Fermand JP; Bridoux F; Jaccard A
    Nephrol Ther; 2011 Nov; 7(6):467-73. PubMed ID: 21497573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].
    Adam Z; Pour L; Krejcí M; Zahradová L; Krivanová A; Mardová J; Kovárová L; Stepánková S; Moulis M; Kren L; Veselý K; Svobodová I; Germáková Z; Nedbálková M; Mayer J; Hájek R
    Vnitr Lek; 2010 Mar; 56(3):190-209. PubMed ID: 20394205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial.
    Shen KN; Fu WJ; Wu Y; Dong YJ; Huang ZX; Wei YQ; Li CR; Sun CY; Chen Y; Miao HL; Zhang YL; Cao XX; Zhou DB; Li J
    Circulation; 2022 Jan; 145(1):8-17. PubMed ID: 34503349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.
    Reece DE; Hegenbart U; Sanchorawala V; Merlini G; Palladini G; Bladé J; Fermand JP; Hassoun H; Heffner L; Vescio RA; Liu K; Enny C; Esseltine DL; van de Velde H; Cakana A; Comenzo RL
    Blood; 2011 Jul; 118(4):865-73. PubMed ID: 21562045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Light chain amyloidosis 2012: a new era.
    Gatt ME; Palladini G
    Br J Haematol; 2013 Mar; 160(5):582-98. PubMed ID: 23294331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis.
    Brennan X; Withers B; Jabbour A; Milliken S; Kotlyar E; Fay K; Ma D; Muthiah K; Hamad N; Dodds A; Bart N; Keogh A; Hayward C; Macdonald P; Moore J
    Intern Med J; 2022 Oct; 52(10):1826-1830. PubMed ID: 36266066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
    Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.